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Dear Editor,
There is a traditional belief that higher costs are as-
sociated with better performance and clinical outcome.
Sure this assumption is not true as far as we go. There is
a need to consider ‘value for money’ in providing health
services (1). In countries with limited financial resources
the importance of clinical decision making based on value
rather than price is doubled. Preliminary investigations
show that there is a room for cost saving measures in all
disciplines of clinical practice without negative impact on
health outcomes. To be accurate, allocating economic re-
sources on a ‘value-based’ approach is more affordable
than ‘free-for-all’ approach (1). However, there are some
public and governmental concerns with this reforming. Is
it ethical to deprive patients from effective but expensive
treatment modalities? Is it reasonable to deprive medical
students from practice with costly treatments and medi-
cations? May this approach fade educational purposes or
research activities? These questions should be asked but
may not stop the process of reforming the allocation of re-
sources on a value-based approach in a reasonable health
care system.
There is no “one-size-fits-all” approach to value-based
practice among medical disciplines. Cost-minimization
analysis is a type of cost-effective analysis where the alter-
natives are considered equivalent. Although the effects
of anesthetics are not equal, their difference is not big
enough to be clinically significant in most of scenarios.
Thus, cost minimization surveys targeting the elimination
of certain medications could be considered reasonable (2).
Regarding the fact that cost of services, devices and medi-
cations are unknown to the majority of clinicians, clarify-
ing the costs is the first step in cost minimization plans. As
a miniature of cost minimization in the discipline of anes-
thesia practice, we estimated the cost of induction and
maintenance of anesthesia with commonly used medica-
tions.
Our survey show that among intravenous anesthet-
ics etomidate is 12 times more expensive than ketamine
and should be reserved for certain conditions. Sodium
thiopental, propofol and benzodiazepines remain reason-
able choices regarding their average cost (Table 1). For
maintenance of anesthesia, sevoflurane is several times
more costly than other anesthetics. As an example, it is
nine times more costly than other commonly used volatile
agent isoflurane. In our center it is a usual practice to ap-
ply inhalation induction of anesthesia with sevoflurane in
small kids without intravenous access. It is wise to switch
from sevoflurane to isoflurane for maintenance of anes-
thesia in pediatrics with comparable safety and efficacy of
volatile agents. Among intravenous drugs, propofol is the
commonly used but expensive choice. In most patients it
could be safely replaced with other medications namely
midazolam especially for maintenance of anesthesia.
It is widely accepted that only in a minority of patients
particular medications may be safer or have superiority
over the cheaper substitutes. Earlier studies have evalu-
ated the effects of limited access to the relatively expensive
drugs of remifentanil, dexmedetomidina and desflurane.
The results demonstrated some drug cost savings without
significant effect on clinical outcomes or duration of hos-
pital stay (3-5). The reasonable approach is to identify cost
contaminant interventions and actively replace the appro-
priate interventions and medications.
A study of surgical costs in the U.S. private setting
showed that operating rooms included 40% of hospital ex-
penses, while 70% of the hospital’s income is from the oper-
ating room (6). Drug costs (anesthetic and non-anesthetic)
account for 6% of the total costs of the hospital, 22% of
which is owned by anesthetic agents. The cost of intraop-
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Table 1. Total Cost of Anesthetic Agents in US Dollar (IRR)
Drugs Induction, $ (IIR)a Maintenance per Hour, $
(IIR)
Propofol (1%) 0.70 (56000) 2.41 (193000)
Propofol (2%) 0.56 (44500) 1.87 (150000)
Sodium thiopental 0.36 (29000) 0.67 (54000)
Midazolam 0.30 (24000) 0.17 (14000)
Diazepam 0.30 (24000) 0.09 (7300)
Ketamine 0.17 (13600) 0.49 (39300)
Etomidate 2.00 (160000) -
Sevoflurane (3%) - 8.04 (643000)
Isoflurane (1.2%) - 0.89 (71500)
a One US dollar in the study period was 80000 IRR on average according to the
formal reports of the central bank of the I.R.Iran with fresh gas flow 3 L.min-1 .
erative anesthetic drugs included only 5.6% of the periop-
erative costs. Despite a small percentage of the total peri-
operative costs of anesthetic drugs, we need to find inter-
ventions that have a reasonable cost to be implemented.
In summary, habitual use of anesthetics without con-
sidering their prices precludes the cost-effective adminis-
tration of them. It should be noted that the existence of a
costly medication in the market does not necessarily trans-
late to higher benefit compared with alternatives. The clin-
icians should restrict the use of these medications when
their added benefit is not proven or is not large enough
to warrant their administration. This strategy will help
to reduce the drug shortages especially in health systems
with limited financial resources. In educational centers,
it is worthwhile to maintain access to multiple anesthetic
drugs for educational and research purposes. Finally, as Sir
Muir Gray, chief knowledge officer, UK National Health Ser-
vice says “Doing things right is only half the story- it is also
essential to use our limited resources most effectively by
identifying and discontinuing lower value activities”.
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